儿科

订阅

MedSci主页 / 所有栏目 / 儿科

Cell Host & Microbe：抗生素，儿科失调和疾病

2015-05-15 佚名 生物谷

抗生素儿科失调疾病
关注

最近来自明尼苏达大学的科学家通过研究揭示了婴儿期抗生素使用、肠道菌群改变及婴儿后期疾病状况之间的三角关系，相关研究发表于Cell Host & Microbe上；肠道菌群失衡即为生态失调，往往会引发多种感染性疾病、过敏症及其它字体免疫障碍，甚至肥胖等。该研究或为临床开发一种预测性的模型来测定幼儿肠道中健康菌群的发育提供帮助。抗生素是目前针对儿童最常用的处方药，其在儿童服用的所有药物中大约占

最近来自明尼苏达大学的科学家通过研究揭示了婴儿期抗生素使用、肠道菌群改变及婴儿后期疾病状况之间的三角关系，相关研究发表于Cell Host & Microbe上；肠道菌群失衡即为生态失调，往往会引发多种感染性疾病、过敏症及其它字体免疫障碍，甚至肥胖等。该研究或为临床开发一种预测性的模型来测定幼儿肠道中健康菌群的发育提供帮助。

抗生素是目前针对儿童最常用的处方药，其在儿童服用的所有药物中大约占到了四分之一，而给儿童服用的三分之一的抗生素都被认为是不必要的，目前已经有研究揭示了抗生素对机体肠道菌群多样性及组成的短期及长期影响。

研究者Dan Knights教授说道，和代谢及免疫系统相关的疾病近年来处于持续增加的势头，然而很多疾病我们并不清楚发病的机制是什么；此前就有研究揭示抗生素使用和肠道菌群失衡的关系，有些研究则阐明了肠道菌群失衡和成年疾病发生的关联；在过去一年里研究人员综合分析了成百上千项研究，发现抗生素使用、肠道菌群改变及成年期疾病发生三者之间存在强相关性。

文章中，研究者开发了一种结构图来绘制抗生素如何在肠道中发挥作用引发成年期疾病，以过敏症为例，抗生素的使用会清除机体中促进免疫细胞成熟的关键肠道细菌，而关键肠道细菌对于维持机体免疫功能非常关键，即便这些关键细菌恢复也不能恢复免疫系统的受损情况；对于肥胖而言，抗生素诱导的肠道维生素的改变或许会导致短链脂肪酸水平的增加，从而影响机体代谢。

Knights表示，本文研究或为后期研究提供一定的研究基础，来确定抗生素使用对个体的健康效益及可能发生的问题；同时也为揭示婴儿期抗生素使用如何影响其成年后疾病的发生提供了一定的研究线索。

原始出处：

Pajau Vangay, Tonya Ward, Jeffrey S. Gerber, Dan Knights.Antibiotics, Pediatric Dysbiosis, and Disease.Cell Host & Microbe, May 13, 2015.DOI: http://dx.doi.org/10.1016/j.chom.2015.04.006

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1869116, encodeId=dbd21869116ca, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Feb 09 07:45:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084124, encodeId=e63a2084124bf, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Jan 24 22:45:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959369, encodeId=07b8195936970, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jan 02 05:45:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857349, encodeId=446d185e349d0, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Nov 30 11:45:00 CST 2015, time=2015-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23878, encodeId=acdb238e8fe, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 17 19:53:00 CST 2015, time=2015-05-17, status=1, ipAttribution=)]
    2016-02-09 zhaozhouchifen

    #Cell#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1869116, encodeId=dbd21869116ca, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Feb 09 07:45:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084124, encodeId=e63a2084124bf, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Jan 24 22:45:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959369, encodeId=07b8195936970, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jan 02 05:45:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857349, encodeId=446d185e349d0, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Nov 30 11:45:00 CST 2015, time=2015-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23878, encodeId=acdb238e8fe, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 17 19:53:00 CST 2015, time=2015-05-17, status=1, ipAttribution=)]
    2016-01-24 xjy02

    #Micro#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1869116, encodeId=dbd21869116ca, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Feb 09 07:45:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084124, encodeId=e63a2084124bf, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Jan 24 22:45:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959369, encodeId=07b8195936970, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jan 02 05:45:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857349, encodeId=446d185e349d0, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Nov 30 11:45:00 CST 2015, time=2015-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23878, encodeId=acdb238e8fe, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 17 19:53:00 CST 2015, time=2015-05-17, status=1, ipAttribution=)]
    2016-01-02 维他命

    #CEL#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1869116, encodeId=dbd21869116ca, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Feb 09 07:45:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084124, encodeId=e63a2084124bf, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Jan 24 22:45:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959369, encodeId=07b8195936970, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jan 02 05:45:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857349, encodeId=446d185e349d0, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Nov 30 11:45:00 CST 2015, time=2015-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23878, encodeId=acdb238e8fe, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 17 19:53:00 CST 2015, time=2015-05-17, status=1, ipAttribution=)]
    2015-11-30 jiafufeng@yaho

    #CRO#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1869116, encodeId=dbd21869116ca, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Feb 09 07:45:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084124, encodeId=e63a2084124bf, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Jan 24 22:45:00 CST 2016, time=2016-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959369, encodeId=07b8195936970, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jan 02 05:45:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857349, encodeId=446d185e349d0, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Nov 30 11:45:00 CST 2015, time=2015-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23878, encodeId=acdb238e8fe, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 17 19:53:00 CST 2015, time=2015-05-17, status=1, ipAttribution=)]
    2015-05-17 huaxipanxing

    看看

    0

相关资讯

震惊！江浙沪儿童一半以上暴露于抗生素

近日，上海复旦大学公共卫生学院公布一份有关“江浙沪儿童普遍暴露于多种抗生素”的研究报告，引起公众广泛关注。这项研究，历经1年，对江苏、浙江、上海1000多名8到11岁在校儿童的尿液监测证实，该地儿童普遍暴露于多种抗生素，背负沉重的抗生素负担。 化验结果让人震惊 有的甚至被检出6种抗生素 化验结果表明，这1000多个样本儿童中，至少有

NEJM：对社区获得性肺炎（CAP）患者使用何种抗生素治疗方案更好（CAP-START研究）？

背景：对于怀疑是社区获得性肺炎（CAP）并且入住普通病房的病人来说，医生依靠经验对病人选择抗生素治疗方案是比较麻烦和复杂的，因为缺乏足够的、可确诊的证据。我们实验的目的在于比较各种不同的经验性治疗方案如β-内酰胺类单一用药治疗、β-内酰胺类与大环内酯类联合治疗、氟喹诺酮类药物单一用药治疗三种方案之间的差异 。结果：一共有656名患者接受β-内酰胺类单一用药治疗；有739名患者接受β-内酰胺类与大环

PLoS Biol：交替使用抗生素可有效“打击”耐药性的细菌

近日，一项刊登在国际杂志PLoS Biology上的研究论文中，来自埃克塞特大学的研究人员通过研究揭开了一种新型技术，其可以帮助抵御抗生素耐药性细菌增长的趋势，耐药性细菌会引发机体患病而且通常会引发威胁生命的疾病。 研究者利用了一种序贯疗法，即利用交替剂量的抗生素来有效抵御细菌的感染；这种进行疗法管理的技术可以降低细菌对抗生素产生耐药性的风险，同时也可以维持药物的长期效力。研究表明，利用两种抗

Mol Microbiol：揭秘耐药菌毒力因子的特殊结构单元或可开发新型抗生素

近日，一项发表于国际杂志Molecular Microbiology上的研究论文中，来自阿德莱德大学的科学家通过研究发现了一种新型靶点，该靶点或为开发抵御引发疾病细菌的新型抗生素提供一定的帮助；文章中研究者鉴别出了对许多细菌毒力因子较为常见的结构单元，细菌的毒力因子是一种可以引发疾病的特殊蛋白质，比如毒素类或降解酶。 这种结构单元名为“旅客”相关的运输重复结构（PATR，Passenger-

外媒：滥用抗生素 2050年将致百万人死亡

外媒称，高盛公司资产管理部前主席、经济学家吉姆•奥尼尔26日表示，中国到2050年将每年有100万人死于对抗生素具有耐药性的“超级病菌”，损失会高达20万亿美元。据法新社3月27日报道，他说：“这个问题不分地区、肤色、种族，假如我们不采取措施，那么，无论你是逊尼派还是什叶派，都会因为AMR丧命。”奥尼尔认为，这个威胁使“中国在过去十年里令人瞩目的经济成就和它巨大的未来发展潜力”处于危险境地。据

Lancet：婴儿呼吸急促且不能转诊时的抗生素治疗

每年肺炎、败血症和脑膜炎导致大约700000名新生儿死亡。基于这些疾病的临床表明的差异很难被区别，所以世界卫生组织WHO推荐医院收治出现可能的严重细菌感染新生儿和1个月大的婴儿，包括发烧（37.5℃及以上）、低温（35.5℃及以下）、呼吸急促（每分钟超过60次）等症状。推荐的治疗方案是肌肉注射或静脉注射抗生素（庆大霉素和青霉素G或阿莫西林）至少7-10天。在许多低中等收入的国家，这种治疗只有在